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Melanoma has always been described as an immunogenic tumor. Until 2011 the standard 
of care in metastatic melanoma was chemotherapy, with response rates between 15-20% 
and without any benefit on survival. Melanoma was the first cancer model to introduce the 
immune-checkpoint inhibitors in clinical practice. In this review the preclinical bases and 
the main clinical studies that led to the approval of the immunotherapy agents will be 
described with insights on combination of immunotherapies of combination and on 
predictive biomarkers of benefit from immunotherapy. 
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Introduction 
Melanoma has always been described as an immunogenic tumor. Despite that, until 2011 
the standard of care in metastatic melanoma was chemotherapy (ChT), with response 
rates ranging between 15-20% and no benefit on overall survival (OS). The only available 
immunological therapy was high-dose interleukin-2 (IL-2), which could induce long-lasting 
responses in a small subset of patients; however, high-dose IL-2 was associated with a 
high rate of severe toxicities1. 
Immune checkpoint inhibitors (ICI) were the first class of therapy shown to improve the 
overall survival for patients with advanced melanoma, and the anti-CTLA-4 antibody 
ipilimumab and the anti-PD-1 antibodies nivolumab and pembrolizumab are now the 
standard of care in everyday clinical practice2. In this review, the preclinical bases and the 
main clinical studies that led to the approval of such immunotherapy agents currently used 
in clinical practice will be described, with insights on combination immunotherapy and 




To be activated, T lymphocytes must recognize an antigen exposed on the surface of the 
antigen presenting cells (APCs) through the major histocompatibility complex (MHC). The 
interaction between the T cell receptor (TCR) and the MHC represents the signal 1 of the 
activation process3 (Figure 1). 
However, T lymphocytes require a second signal (signal 2) to complete their activation. 
This signal derives from the interaction between the CD28 co-stimulatory receptor and the 
CD80 and CD86 molecules (also known as B7.1 and B7.2), expressed on the surface of 
APCs cells. The peculiarity of signal 2 is that the interaction of CD28 can be displaced by 
another receptor expressed on the surface of the cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4). This is an inhibitory receptor and, besides, it has greater affinity for 
the B7 molecules than CD283. 
From a physiological point of view, CTLA-4 is essentially involved in the reduction of the T 
helper cells (Th) activity and in the strengthening of regulatory T cells (TRegs), a sub-
category of T lymphocytes which is strictly involved in the maintaining self-tolerance and 
where CTLA-4 is constitutively expressed3. 
CTLA-4 is a target gene of the Forkhead box P3 transcription factor (FOXP3), a crucial 
factor in the genesis of TRegs cell lineage4. The role of CTLA-4 and the function of TRegs is 
closely related. In fact, persons bearing the homozygous mutation in FOXP3 present the 
clinical signs of a particular autoimmune hereditary syndrome, known as IPEX, an X-linked 
inheritance disease, which includes: immune dysregulation, polyendocrinopathy and 
enteropathy5. These clinical manifestations are very close to the main side effects of the 
anti-CTLA-4 antibodies observed in clinical studies and in clinical practice. 
The inhibition of CTLA-4 is a therapeutic strategy which is therefore based on both the 
enhancement of the T CD4 effector lymphocytes and the inhibition of TRegs lymphocytes. 
Allison and colleagues showed that despite this immune-checkpoint was not tumor-specific 
there could still be a rationale for a clinical study with an anti-CTLA-4 agent in some 
immunogenic tumors. 
Tremelimumab and ipilimumab were the first fully humanized anti-CTLA-4 antibodies that 
were clinically tested in 2000. 
In the case of tremelimumab, a phase 3 randomized clinical trial showed no benefit in 
terms of survival compared to dacarbazine, with a high rate of immune-related adverse 
events (irAEs)6. 
On the other hand, for ipilimumab, less toxic doses were studied and the algorithms for the 
management of immunological toxicities have been improved, resulting in an overall 
reduction of mortality and morbidity, and in an advantage in terms of survival in melanoma. 
In particular, two phase 3 clinical studies (CA 184-002 and CA 184-024) led to the 
approval of ipilimumab by U.S. Food and Drug Administration (FDA). 
In CA 184-002, a total of 676 previously treated patients were randomized (in a 3:1:1 ratio) 
to receive ipilimumab 3 mg/kg + gp100 (Melanoma Peptide Vaccine) vs. ipilimumab 3 
mg/kg + placebo vs. gp100 alone. Ipilimumab showed an advantage in terms of median 
overall survival (OS) of 3.6 months: the median OS was 10.1 months among patients in 
the ipilimumab alone arm (HR for death in comparison with gp100 alone 0.66; p=0.003), 
with no difference in OS between the ipilimumab arms (HR 1.04; p=0.76); median OS was 
6.4 months in the gp100 vaccine alone group7,8. 
The CA184-024 study compared ipilimumab 10 mg/kg + dacarbazine (DTIC) vs. DTIC 
alone in naïve patients. Ipilimumab showed a significant improvement in terms of survival 
rates at 3 years (20.8% vs. 12.2% in the ipilimumab + DTIC and DTIC alone arms, 
respectively). HR for death in the ipilimumab + DTIC treatment arm was 0.72; p=0.0019. 
 
Ipilimumab led to a significant advantage in term of clinical response and OS in patients 
with metastatic melanoma, but irAEs associated with such treatment are a challenging limit 
in clinical practice. CTLA-4 is an important immune check-point implicated in the 
maintenance of immunologic homeostasis, and when blocked, it can induce immune-
toxicity. The most frequently observed ipilimumab-induced irAEs are: rashes, colitis, 
hepatitis and endocrinopathies. In particular, a difference has been observed between the 
3 mg/kg dose group and the 10 mg/kg dose. Treatment-related serious AEs were 37% vs. 
18% (in the 10 mg/kg and in the 3 mg/kg dose, respectively), with four (1%) vs. two (<1%) 
treatment-related deaths. The 3 mg/kg dose showed to be more favorable in terms of 
safety, with no loss in terms of efficacy10. However, even if the FDA approved dose is now 
3 mg/kg, a lower dose should still be experimented in order to create a more suitable 







PD-1 receptor has a consistent action on the immuno-escaping mechanisms within the 
tumor microenviroment3. PD-1 is an immunological checkpoint inhibiting the lymphocyte 
activity in the peripheral tissue when the immunological specific response has already 
been established, unlike CTLA-4 which is involved during the T lymphocyte activation 
phase3. The PD-1 ligands are PD-1 ligand 1 (PD-L1, also known as B7-H1) and PD-1 
ligand 2 (PD-L2, also known as B7-DC)3 (Figure 2). 
The PD-1 receptor is expressed on the surface of the activated T lymphocyte, causing its 
exhaustion and, similarly to CTLA-4, PD-1 is expressed at high levels as well on the 
surface of Treg lymphocytes3. Unlike CTLA-4, PD-1 expression can be induced not only 
on the T cell surface, but also on other subsets of activated lymphocytes, such as B and 
NK cells11, being widespread on a higher number of different immunologic actors. 
Therefore, the PD-1 blockade increases the NK cell cytotoxicity within the tumor, as well 
as the antibody activity mediated by the B lymphocytes expressing PD-1. 
This immune-checkpoint is particularly relevant in inducing a state of exhaustion or anergy 
among the specific T lymphocytes chronically exposed to the antigen, as in the case of 
chronic viral infections and cancer. Therefore, the PD-1 blockade has a role in the 
reinvigoration of the anergic effector cells, blocking the immunological exhaustion 
provoked by chronic antigenic stimulation3. 
 
Figure 1. Distinct mechanism of the CTLA-4 and PD-1 immune checkpoints. 
1. CTLA-4 blocks the co-stimulatory link between the CD28 receptor, expressed on the surface of the naïve T cells, and 
the CD80/CD86 molecules, during T cell activation, leading to an inhibitory signal. 
2. On the contrary, the PD-1 receptor is expressed on the surface of effector T cells, playing a role in the peripheral site 
of the immune response, its expression is directly induced by the inflammatory response itself. Actually, during the 
chronic antigen exposure states, PD-1 can lead to the T cells exhaustion.  
Thanks to these preclinical bases, the fully human IgG4 anti-PD-1 nivolumab and the fully 
humanized IgG4 anti-PD-1 pembrolizumab achieved revolutionary outcomes in clinical 
trials leading to their approval by the regulatory agencies in 2014. 
In the randomized controlled phase 3 clinical study CheckMate 037, nivolumab 3 mg/kg 
every two weeks was compared to an investigator choice chemotherapy (ChT) in 370 
melanoma advanced disease patients, pretreated with ipilimumab or BRAF inhibitors. The 


















nivolumab arm: 31.7% and 10.6%, respectively. Concerning the toxicity rate, fatigue, 
pruritus and diarrhea were the most observed toxicities in the nivolumab arm. 
Furthermore, grade 3-4 (G3-4) toxicity was observed in 9% of patients in the nivolumab vs. 
31% in the ChT arm, and, in particular, the main G3-4 toxicities observed in the nivolumab 
arm were increased lipase, increased alanine aminotransferase, fatigue and anemia12. 
Nivolumab was also studied in a first-line setting, compared with DTIC in BRAF wild-type 
melanoma patients, in the phase 3 clinical study CheckMate 066. The primary endpoint 
was OS. The 3-year OS was 51.2% vs. 21.6% in the nivolumab and the DTIC arms, 
respectively. The main irAEs were diarrhea and elevated alanine aminotransferase 
level13,14. 
The randomized phase 3 clinical trial KEYNOTE-006 compared the efficacy of 
pembrolizumab vs. ipilimumab in checkpoint-inhibitor-naive melanoma advanced disease 
patients. The study randomized 834 patients in 1:1:1 to receive pembrolizumab 10 mg/kg 
every two weeks or every three weeks or four doses of ipilimumab 3 mg/kg every three 
weeks. Pembrolizumab was administered until disease progression, unacceptable toxicity 
or 24 months of therapy. Furthermore, patients with confirmed complete responses who 
received pembrolizumab for at least 6 months could discontinue therapy after receiving 
two cycles following the achievement of confirmed complete response. The primary 
endpoints were OS and progression free survival (PFS). In the 4-years update, presented 
at ASCO 2018, the OS data for treatment-naive patients were 44.3% for patients who 
received pembrolizumab vs. 36.4% in the ipilimumab arm, with a 4-years PFS of 36.2% for 
pembrolizumab vs.15.9% for ipilimumab15,16. Concerning adverse events, the most 
common observed AE in the pembrolizumab arms were fatigue, diarrhea, rash and 
pruritus. While the most frequently observed irAEs in the pembrolizumab arms were 
hypothyroidism (10.1% and 8.7% in the q14 and q21 schedules, respectively), 
hyperthyroidism (6.5% and 3.2%), of which G3-4 were mainly colitis (1.4% and 2.5%) and 
hepatitis (1.1% and 1.8%). In the ipilimumab arm the most observed irAE was colitis 
(8.2%), while the main G3-4 were colitis (7.0%) and hypophysitis (1.6%)17. 
In this clinical trial, the possibility of discontinuing an immune-checkpoint inhibitor after 24 
months of treatment has been studied, enhancing the concept of the achievement of the 
immunological memory leading to sustained and prolonged objective responses over time. 
See Table 19,12,14,17,18 for a summary of data from the phase 3 clinical trials of 
immunotherapy in melanoma. 
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Table 1. Overview of the principal immunotherapy clinical trials in metastatic melanoma. 
  
Combination of Immune-checkpoint inhibitors 
The encouraging preclinical and clinical results obtained with immune-checkpoint inhibitors 
as single agents have led the investigators to study the possibility of combining 
immunotherapeutic agents with different mechanisms of action. 
In particular, the phase 3, clinical study CheckMate 067 randomized 1:1:1 a total of 945 
naive patients with advanced melanoma, stratified by BRAF mutational status, AJCC M 
stage, and PD-L1 tumor expression, to receive nivolumab 1 mg/kg + ipilimumab 3 mg/kg 
every three weeks for 4 doses then nivolumab 3 mg/kg every two weeks, or nivolumab 3 
mg/kg every two weeks + ipilimumab-matched placebo, or ipilimumab 3 mg/kg every three 
weeks for 4 doses + nivolumab-matched placebo. The primary endpoints were PFS and 
OS compared between the arms containing nivolumab and the ipilimumab arm. 
The 4-years data showed a PFS of 37%, 31% and 9%, in the nivolumab + ipilimumab, 
nivolumab and ipilimumab arms, respectively. The 4-years OS  were 53%, 46% and 30%, 
in the nivolumab + ipilimumab, nivolumab and ipilimumab arms, respectively19. Even if the 
study was not designed to statistically demonstrate the superiority of the nivolumab + 
ipilimumab regimen vs. nivolumab alone, the RR, PFS and OS of the combination regimen 
appeared superior to those of nivolumab alone. In addition, CheckMate 067 is the second 
phase 3 clinical trial after the KEYNOTE-006 trial which confirms the superiority of an anti-
PD-1 vs. an anti-CTLA-4. 
The patients stratification based on the level of intratumoral expression of PD-L1 showed 
that the immuno-combination therapy gives an advantage of about 10% over the 
nivolumab monotherapy in terms of OS, when the PD-L1 expression level is < 1%, while 
the OS curves are substantially overlapping when the PD-L1 level is ≥1%. 
However, these results were obtained at the expense of a high toxicity profile. In fact, 59% 
of patients who received nivolumab + ipilimumab showed G3-4 AEs, vs. 22% and 28 % in 
the nivolumab and ipilimumab arms, respectively. The most important G3 AEs were 
diarrhea and colitis in all treatment arms18,19. 
Based on these results, the nivolumab + ipilimumab combination has been approved by 
the regulatory authorities. 
In order to overcome the obstacle of the high toxicity profile, the investigators evaluated in 
a phase 1 study pembrolizumab + low dose ipilimumab (1 mg/kg) for four cycles every 
three weeks, followed by pembrolizumab alone. This combination showed an incidence of 
G3-4 AEs of 42% and an ORR of 57%20. 
CheckMate 511 was a phase 3b/4 trial conducted to determine if nivolumab 3 mg/kg + 
ipilimumab 1 mg/kg (NIVO3+IPI1) had a better toxicity profile than the approved nivolumab 
1 mg/kg + ipilimumab 3 mg/kg (NIVO1+IPI3) combination. The primary endpoint was the 
incidence of treatment-related G3-G5 AEs in the two arms. Incidence of G3-5 AEs was 
significantly lower in the NIVO3+IPI1 arm compared with NIVO1+IPI3 (34% vs. 48%; 
p=0.006).21 Despite the study was not designed to demonstrate the noninferiority of 
NIVO3+IPI1 to NIVO1+IPI3 for efficacy, the observed ORR was 45.6% in the NIVO3+IPI1 
arm vs. NIVO1+IPI3 arm, with a median PFS of 9.9 months in the NIVO3+IPI1 arm and 
8.9 months in the NIVO1+IPI3 arm21. 
The phase 3 clinical trial KEYNOTE-252 compared the efficacy of pembrolizumab vs. 
pembrolizumab + epacadostat, an indoleamine 2,3-dioxygenase (IDO) enzyme inhibitor, 
implicated in the mechanisms of immunotolerance and immunoescape. However, despite 
the promising results of phase 1-2, the 1-year observed PFS and OS in the two arms were 
similar22. Other combinations of anti-PD-1 plus the immune-checkpoint lymphocyte 
activation gene-3 (LAG-3) inhibitor are under evaluation. 
Finally, the Part 3 of the clinical study KEYNOTE-022 data have been recently presented. 
A total of 120 naïve melanoma advanced disease patients bearing the BRAF V600E/K 
mutation, were randomized to receive dabrafenib + trametinib + pembrolizumab 2 mg/kg 
every three weeks or dabrafenib + trametinib + placebo, even if the two arms were not 
balanced in terms of different stage IV subtypes with prevalence of M1c in the 
experimental arm with respect to the placebo arm (82% vs. 63%). The primary endpoint 
was PFS, which was numerically higher in the dabrafenib + trametinib + pembrolizumab 
arm (1-year PFS 59% vs. 45%) but did not reach the established threshold of significance 
as per study design. In the experimental arm, even if such difference was not statistically 
significant, more CRs were observed (18.3% vs. 13.3%), with a greater number of G3-4 
AEs (57% vs. 27% treatment-related AEs)23. It should be noted, however, that 50% of 
patients in the placebo arm received immunotherapy at disease progression. A more 
extended follow-up could clarify whether the initial differences seen in PFS and response 
duration will be confirmed. 
  
Brain metastasis 
The presence of brain metastases is associated with poor prognosis in advanced 
melanoma patients, and they still represent a crucial therapeutic challenge. Furthermore, 
brain metastases have been an exclusion criteria from the majority of clinical studies24. 
Recently, two clinical studies investigated the efficacy of the combination of nivolumab + 
ipilimumab in these patients. 
The CheckMate 204 trial is a phase 2 clinical trial which included patients with at least one 
≥5 mm, non-irradiated brain metastasis, in absence of neurological symptoms. Patients 
received nivolumab 1 mg/kg + ipilimumab 3 mg/kg in the induction phase every three 
weeks for four cycles, followed by nivolumab 3 mg/kg every two weeks. The primary 
endpoint was the intracranial clinical benefit (an endpoint consisting of CR, PR and SD for 
more than 6 months). The observed intracranial response rate was 57% (with a 26% of 
CR). After one year, the observed PFS and OS were 60% and 82%, respectively. G3-4 
AEs were reported in 55% of patients25. The experimental therapy has therefore shown 
good local and systemic disease control. 
The ABC (Anti-PD-1 Brain Collaboration) Trial is another phase 2 clinical trial with similar 
inclusion criteria to CheckMate 204, but included three cohorts: asymptomatic patients 
were randomized or in Cohort A, receiving nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 
three weeks for four cycles, followed by nivolumab 3 mg/kg every two weeks, or in Cohort 
B, receiving nivolumab 3 mg/kg every two weeks. While, locally pretreated, symptomatic, 
or with leptomeningeal involvement, received instead nivolumab 3 mg/kg every two weeks. 
The primary endpoint was the intracranial response at week 12. The Cohort A showed 
intracranial ORR comparable to that observed in CheckMate 204. While patients who 
received nivolumab monotherapy showed, in Cohort B (asymptomatic) an ORR of 21%, 
and in the Cohort C (symptomatic) an ORR of 6%26. This study confirmed as well that the 
combination of nivolumab + ipilimumab should be considered as a first-line therapy for 
patients with untreated and asymptomatic melanoma brain metastases. 
However, these encouraging data does not involve patients with symptomatic brain 




The pursuit of a biomarker 
Immune-checkpoint inhibitors and in particular the anti-PD-1 agents showed an important 
antitumor effect with increased ORRs and an improved survival in melanoma and multiple 
other cancers patients. However, not all patients respond to such treatment, and in order 
to understand if there is a way to predict which patients will respond to immune-checkpoint 
inhibitors, many biomarkers have been tested. 
From a clinical point of view, the most important, predictive biomarker is serum lactate 
dehydrogenase (LDH). High baseline levels of serum LDH have been associated to a less 
favorable outcome in terms of response rate, OS and PFS in patients treated both with 
targeted therapy (3-years OS 55% vs. 22% in normal and elevated serum LDH, 
respectively)27, and immunotherapy with an anti-PD-1 (4-years OS 54% vs. 31% in normal 
and elevated serum LDH, respectively) and with an anti-CTLA-4 (4-years OS 38% vs. 17% 
in normal and elevated serum LDH, respectively)19. 
In particular, the most important described biomarkers can be classified into two 
categories, as illustrated by Cristescu in a recent article analyzing the predictive 
biomarkers of response to pembrolizumab: (1) those related to tumor neoantigen burden, 
such as the microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) or high 
tumor mutational burden (TMB); and (2) those related to T cell-inflammed tumor 
microenvironment (TME), such as the expression by tumor cells and immune system cells 
of PD-L1 at different levels, and the gene signatures of activated T cells. 
In a pan-tumor cohort, it was observed that high levels of both TMB and T cell-inflammed 
tumor gene expression profile (GEP) are predictive of the response to pembrolizuamb and 
give significant advantage in terms of PFS28. 
On this basis, the U.S. Food and Drug Administration (FDA) has approved the use of 
nivolumab for the treatment of certain cancers (such as metastatic colorectal cancer) 
having MSI-H/dMMR, and pembrolizumab for any solid tumor with MSI-H/dMMR. 
Concerning the immunogenicity of tumors, Galon and colleagues suggested that it is 
essential to understand the mechanisms underlying hot, altered and cold tumors in order 
to use the correct therapy for the right tumor, activate the specific immune response and 
convert immune cold tumors into immune hot29. Hot tumors present a high T specific 
lymphocyte infiltrate, even if mainly with an exhausted phenotype expressing high levels of 
inhibitory receptors, and in particular CTLA-4 and PD-1. For this reason, they represent 
the best substrate for therapy with immune-checkpoint inhibitors, as single agents or in 
combination with each other. Based on preclinical data, chronic interferon response can 
lead to the immune-checkpoint inhibitors resistance, while the use of co-stimulatory 
molecules, although promising, is clinically limited by the high toxicity profile. 
In addition to the use of immune-checkpoint inhibitors, recent studies showed how 
microbiota can influence the development of a hot tumor microenvironment. For example, 
mice receiving fecal microbiota transplantation from immune-checkpoint inhibitors 
responder patients presented an upregulation of PD-L130. In excluded tumors, instead, 
there is an accumulation of T CD8 lymphocytes around the tumor, without an actual 
infiltrate. The host is able to mount a specific immune response, but there is physical 
inability to reach the tumor. This disability may be due to a lack of chemokines resulting 
from modulation of genetic and epigenetic pathways responsible of their expression. For 
example, DNA methylation can reduce the levels of CXCL9 and CXCL10 in some 
tumors31,32. Another reason could be the barrier effect resulting from an ineffective tumor 
vascularization, which could benefit from the combination of immune-checkpoint inhibitors 
with anti-angiogenic agents33.  
Another reason for the failure to develop an adequate adaptive immune response is the 
failure to activate the innate response. For this reason, the antineoplastic potential of Toll-
like receptors (TLR) has been studied. In particular, the intratumoral injection of TLR9 
agonist in combination with immune-checkpoint inhibitors34,35. 
Cold tumors are associated with poor prognosis. The proposed strategy to convert them 
into hot tumors is the combination of a priming phase that activates the specific T 
lymphocyte response with, for example, vaccines, adoptive T cell transfer, with immune-
checkpoint inhibitors or co-stimulatory molecules. Other approaches may include radiation 




The introduction of immune-checkpoint inhibitors, and in particular of anti-PD-1/PD-L1 
agents, has not only revolutionized the therapeutic paradigm in melanoma, leading to 
long-lasting responses in almost half of patients, but also in an increasing number of 
tumors. However, clinical and translational research should focus on the non-responders 
subset of patients, in order to convert the immune-cold tumors into immune-hot ones. As 
suggested by Galon29, the approach should be multimodal and based on a preclinical 
rationale, identifying the characteristics of the tumor immune infiltrate, the activation status 
of the adaptive and the innate response as well, and the ability of the tumor-specific 
lymphocytes to reach the tumor bed. Moreover, the immunological characterization should 
go along with the TMB characterization, in order to plan a personalized therapeutic 
strategy. The colder the tumor, the more different therapeutic approaches will be 
needed29. However, even in hot tumors the anti-PD-1 monotherapy is not sufficient to 
achieve the maximal efficiency. 
Further studies are still needed to identify the role of the microbiota in antitumor immunity, 
especially from a clinical-practice point of view. Finally, more efforts should be addressed 
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